Abstract

Coronary artery stenting is increasingly used as a treatment for coronary artery disease. A period of anti-platelet therapy is mandatory following coronary stenting, in order to minimise the risk of stent thrombosis. Approximately 5% of patients who undergo coronary stenting will require noncardiac surgery within 12 months, and the management of antiplatelet therapy in this setting is complex, requiring a balance between the risks of both operative haemorrhage, and stent thrombosis. We review the available evidence to guide decision making with regard to the management of antiplatelet therapy in this setting.